Archive January 3, 2023 Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product Company
Archive January 3, 2023 Deciphera Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK® in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only
Archive January 3, 2023 Deciphera Pharmaceuticals, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference
Archive December 1, 2022 Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities Hematology and Oncology Summit
Archive November 8, 2022 Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences
Archive November 3, 2022 Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results
Archive October 27, 2022 Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022
Archive September 11, 2022 Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT at the European Society for Medical Oncology (ESMO) Congress 2022
Archive September 10, 2022 Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022
Archive September 1, 2022 Deciphera Pharmaceuticals, Inc. to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss DCC-3116 and Vimseltinib Data Presented at ESMO Congress 2022
